On Thursday, Morgan Stanley adjusted its outlook on Amicus (NASDAQ:FOLD) Therapeutics (NASDAQ:FOLD), reducing the price target to $19 from the previous $20. Despite the price target cut, the firm retained its Underweight rating on the stock. This adjustment came after Amicus Therapeutics reported its first-quarter earnings.
The earnings for the quarter were on par with expectations for Galafold, the company's leading product, but fell short for Pombiliti and Opfolda (P+O). The company also revised its revenue growth guidance for Galafold and, notably, provided initial guidance for P+O.
Amicus Therapeutics' financial performance in the first quarter has prompted the firm to reassess the potential revenue trajectory for the company's portfolio. The updated guidance for Galafold suggests changes in the anticipated revenue growth, which is a key factor for investors monitoring the company’s progress.
The new guidance provided for Pombiliti and Opfolda marks the first time the company has offered projections for these products. This development provides a clearer picture of the company's expectations for its product line and its potential impact on future revenues.
The adjustment of the price target by Morgan Stanley reflects the latest financial data and the company's updated guidance. Investors may consider this information as they evaluate Amicus Therapeutics' stock performance and future prospects in the biotechnology market.
InvestingPro Insights
Amicus Therapeutics' recent financial performance and updated guidance have caught the eye of analysts and investors. According to real-time data from InvestingPro, the company has a market capitalization of $2.82 billion and is trading near its 52-week low, which could signal a potential entry point for investors looking at long-term growth prospects. Impressively, Amicus boasts a gross profit margin of 90.65% over the last twelve months as of Q4 2023, highlighting its ability to maintain profitability on its products.
InvestingPro Tips indicate that while Amicus operates with a moderate level of debt, it has liquid assets that exceed its short-term obligations, providing some financial flexibility. However, it's worth noting that the company has not been profitable over the last twelve months, and analysts have recently revised their earnings downwards for the upcoming period. On the upside, analysts predict the company will be profitable this year, which could be a pivotal point for the company's financial trajectory.
Investors looking to delve deeper into Amicus Therapeutics' performance metrics and gain access to exclusive insights can find an additional 9 InvestingPro Tips at https://www.investing.com/pro/FOLD. For those considering a subscription, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, adding even more value to your investment research.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.